Wenbin B. Qian

88 Jiefang Road
Hangzhou, 310009, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 205 publications

Predicting CAR-T outcomes in R/R DLBCL: a multicenter real-world study of a 5-index model.

Predicting CAR-T outcomes in R/R DLBCL: a multicenter real-world study of a 5-index model.

Journal: Frontiers in immunology

Published: April 23, 2026

Long-term follow-up of third generation anti-CD30 CAR T-cell therapy in relapsed/refractory CD30+ lymphomas: a single-arm, multicentre, phase 1-2 trial.

Long-term follow-up of third generation anti-CD30 CAR T-cell therapy in relapsed/refractory CD30+ lymphomas: a single-arm, multicentre, phase 1-2 trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 06, 2026

Safety and efficacy of low-dose, cord blood-derived CD19 CAR-NK cells with 4-1BB co-stimulation in refractory systemic lupus erythematosus.

Safety and efficacy of low-dose, cord blood-derived CD19 CAR-NK cells with 4-1BB co-stimulation in refractory systemic lupus erythematosus.

Journal: Med (New York, N.Y.)

Published: March 12, 2026

A ROS-Responsive Dimeric Prodrug Nanoassembly for Amplified Epigenetic Therapy of Lymphoma.

A ROS-Responsive Dimeric Prodrug Nanoassembly for Amplified Epigenetic Therapy of Lymphoma.

Journal: Journal of medicinal chemistry

Published: March 01, 2026

Zanubrutinib-based regimen as the salvage or bridging treatment of CART therapy in relapsed or refractory, non-germinal center B-cell-like diffuse large B-cell lymphoma: a retrospective multicenter cohort study.

Zanubrutinib-based regimen as the salvage or bridging treatment of CART therapy in relapsed or refractory, non-germinal center B-cell-like diffuse large B-cell lymphoma: a retrospective multicenter cohort study.

Journal: Frontiers in immunology

Published: February 07, 2026

Integrated Genomic and Tumor Microenvironment Subtyping Improved Risk Stratification in Primary Central Nervous System Lymphoma.

Integrated Genomic and Tumor Microenvironment Subtyping Improved Risk Stratification in Primary Central Nervous System Lymphoma.

Journal: American journal of hematology

Published: February 06, 2026

Treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with multiple myeloma: longer follow-up of the real-world MMY4032 study.

Treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with multiple myeloma: longer follow-up of the real-world MMY4032 study.

Journal: Annals of hematology

Published: December 15, 2025

Targeting the HERV-K102 envelope elicits pyroptosis and represents a novel therapeutic strategy for acute myeloid leukemia.

Targeting the HERV-K102 envelope elicits pyroptosis and represents a novel therapeutic strategy for acute myeloid leukemia.

Journal: Blood research

Published: October 29, 2025

Esterase-activatable dimeric HDAC inhibitor nanotherapeutics for enhanced lymphoma epigenetic therapy.

Esterase-activatable dimeric HDAC inhibitor nanotherapeutics for enhanced lymphoma epigenetic therapy.

Journal: Colloids and surfaces. B, Biointerfaces

Published: October 28, 2025

Covalent Bruton's tyrosine kinase inhibitor HZ-A-018 in patients with relapsed or refractory B cell malignancies: A multicenter phase I study.

Covalent Bruton's tyrosine kinase inhibitor HZ-A-018 in patients with relapsed or refractory B cell malignancies: A multicenter phase I study.

Journal: iScience

Published: September 16, 2025

Lateral Orbital Rim Advancement and Balanced Orbital Decompression for Exorbitism Regression in Crouzon Syndrome.

Lateral Orbital Rim Advancement and Balanced Orbital Decompression for Exorbitism Regression in Crouzon Syndrome.

Journal: International journal of oral and maxillofacial surgery

Published: August 27, 2025

CD33KO-CD33-mesothelin Loop CAR design avoids fratricide and improves efficacy of iNK cells against acute myeloid leukemia.

CD33KO-CD33-mesothelin Loop CAR design avoids fratricide and improves efficacy of iNK cells against acute myeloid leukemia.

Journal: Journal for immunotherapy of cancer

Published: August 22, 2025

Showing 1-12 of 205

Last Updated: 09/26/2026